Arrowhead plans webinar on Alzheimer’s drug ARO-MAPT
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc stock price live, this page displays NASDAQ ARWR stock exchange data. View the ARWR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arrowhead Pharmaceuticals Inc real time stock price chart below.
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 64.79.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock ticker symbol for Arrowhead Pharmaceuticals Inc is ARWR.
Is ARWR the Same as $ARWR?
$ARWR is a common way to refer to the Arrowhead Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Arrowhead Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 64.79.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock ticker symbol for Arrowhead Pharmaceuticals Inc is ARWR.
Is ARWR the Same as $ARWR?
$ARWR is a common way to refer to the Arrowhead Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Arrowhead Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.50
65.76
52 wk Range
34.61
95.49
ARWR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
64.5065.76
52 wk Range
34.6195.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARWR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
107.23
Upside
+65.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 107.23
(+65.51% Upside)
Arrowhead Pharmaceuticals Inc SWOT Analysis
Market Outlook | Analysts project significant revenue growth, with price targets ranging from $40 to $80, reflecting optimism about Arrowhead's potential in the evolving RNAi therapeutics landscape. |
Financial Fortitude | Delve into Arrowhead's robust financial position, with a $1.1 billion cash reserve and strong partnerships, providing runway into 2028 for advancing its pipeline. |
Pipeline Potential | Explore Arrowhead's strategic focus on high-value indications in cardiometabolic diseases, including promising programs for FCS, sHTG, and obesity treatments. |
RNAi Pioneer's Milestone | Arrowhead Pharmaceuticals nears its first potential drug approval with plozasiran, validating its TRiM platform and setting the stage for future growth across its diverse pipeline. |
Arrowhead Pharmaceuticals Inc Earnings Call Summary for Q3/2026
- Q3 revenue hit $75.2M, beating estimates by 43% on collaboration income and REDEMPLO sales; net loss widened to $1.36/share vs $1.20 expected.
- REDEMPLO prescriptions doubled quarter-over-quarter; Phase III severe hypertriglyceridemia trials met all endpoints, targeting $3B-$4B peak sales.
- Company plans supplemental NDA filing for larger SHTG indication before end of 2026, using priority review voucher to accelerate approval timeline.
- Operating expenses rose to $245M from $193M year-over-year as company expands commercial operations and late-stage pipeline development.
- Stock climbed 4.16% to $89.59, near 52-week high; management highlighted $1.6B cash position and September data readouts for ARO-MAPT, ARO-DIMER-PA.
Last Updated: 08/04/2026, 05:52 PM
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
-1.36 / -1.20
Revenue / Forecast
75.23M / 52.66M
Compare ARWR to Peers and Sector
Metrics to compare | ARWR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARWRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −28.6x | 3.6x | −0.4x | |
PEG Ratio | 0.29 | 0.93 | 0.00 | |
Price / Book | 19.7x | 4.2x | 2.6x | |
Price / LTM Sales | 13.7x | 3.4x | 3.0x | |
Upside (Analyst Target) | 64.8% | 52.6% | 56.4% | |
Fair Value Upside | Unlock | 20.0% | 7.9% | Unlock |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Arrowhead Pharmaceuticals (ARWR) Stock Price Today?
The Arrowhead Pharmaceuticals stock price today is 64.79 USD.
What Stock Exchange Does Arrowhead Pharmaceuticals Trade On?
Arrowhead Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Arrowhead Pharmaceuticals?
The stock symbol for Arrowhead Pharmaceuticals is "ARWR."
What Is the Arrowhead Pharmaceuticals Market Cap?
As of today, Arrowhead Pharmaceuticals market cap is 9.15B USD.
What Is Arrowhead Pharmaceuticals's Earnings Per Share (TTM)?
The Arrowhead Pharmaceuticals EPS (TTM) is -2.28.
When Is the Next Arrowhead Pharmaceuticals Earnings Date?
Arrowhead Pharmaceuticals will release its next earnings report on Nov 30, 2026.
From a Technical Analysis Perspective, Is ARWR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arrowhead Pharmaceuticals Stock Split?
Arrowhead Pharmaceuticals has split 2 times.
How Many Employees Does Arrowhead Pharmaceuticals Have?
Arrowhead Pharmaceuticals has 711 employees.
What is the current trading status of Arrowhead Pharmaceuticals (ARWR)?
As of Oct 02, 2026, Arrowhead Pharmaceuticals (ARWR) is trading at a price of 64.79 USD, with a previous close of 64.79 USD. The stock has fluctuated within a day range of 64.50 USD to 65.76 USD, while its 52-week range spans from 34.61 USD to 95.49 USD.
What Is Arrowhead Pharmaceuticals (ARWR) Price Target According to Analysts?
The average 12-month price target for Arrowhead Pharmaceuticals is 107.23 USD, with a high estimate of 126 USD and a low estimate of 74 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +65.51% Upside potential.
What Is the ARWR Premarket Price?
ARWR's last pre-market stock price is 65.30 USD. The pre-market share volume is 610.00, and the stock has decreased by -0.15, or -0.23%.
What Is the ARWR After Hours Price?
ARWR's last after hours stock price is 64.35 USD, the stock has decreased by -0.44, or -0.68%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.